{"id":22799,"date":"2022-07-04T07:57:05","date_gmt":"2022-07-04T05:57:05","guid":{"rendered":"https:\/\/vilkaviskiovsb.lt\/?p=22799"},"modified":"2022-07-04T07:57:05","modified_gmt":"2022-07-04T05:57:05","slug":"geros-zinios-pacientams-atnaujinta-kraujo-kresejima-stabdanciu-vaistu-kompensavimo-tvarka","status":"publish","type":"post","link":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/2022\/07\/04\/geros-zinios-pacientams-atnaujinta-kraujo-kresejima-stabdanciu-vaistu-kompensavimo-tvarka\/","title":{"rendered":"Geros \u017einios pacientams \u2013 atnaujinta kraujo kre\u0161\u0117jim\u0105 stabdan\u010di\u0173 vaist\u0173 kompensavimo tvarka"},"content":{"rendered":"<p><strong><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-22800 size-full\" src=\"https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/07\/20402_24261e79e101a2baeef145fcc78b1724.png?resize=852%2C536&#038;ssl=1\" alt=\"\" width=\"852\" height=\"536\" srcset=\"https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/07\/20402_24261e79e101a2baeef145fcc78b1724.png?w=852&amp;ssl=1 852w, https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/07\/20402_24261e79e101a2baeef145fcc78b1724.png?resize=300%2C189&amp;ssl=1 300w, https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/07\/20402_24261e79e101a2baeef145fcc78b1724.png?resize=768%2C483&amp;ssl=1 768w, https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/07\/20402_24261e79e101a2baeef145fcc78b1724.png?resize=18%2C12&amp;ssl=1 18w\" sizes=\"auto, (max-width: 852px) 100vw, 852px\" \/><\/strong><\/p>\n<p><strong>Dar daugiau didel\u0117s rizikos pacient\u0173, apdraust\u0173 privalomuoju sveikatos draudimu, gal\u0117s \u012fsigyti kompensuojam\u0173j\u0173 kraujo kre\u0161\u0117jim\u0105 stabdan\u010di\u0173 vaist\u0173 (antikoaguliant\u0173). Tai pasiekta Sveikatos apsaugos ministerijai patikslinus \u0161i\u0173 vaist\u0173 kompensavimo tvark\u0105. Numatoma, kad i\u0161laidos antikoaguliantams suma\u017e\u0117s beveik 9 t\u016bkst. \u017emoni\u0173, kurie dabar \u0161iuos vaistus \u012fsigyja savo l\u0117\u0161omis.\u00a0<\/strong><\/p>\n<p>Lig\u0173 ir kompensuojam\u0173j\u0173 vaist\u0173 joms gydyti s\u0105ra\u0161e (A s\u0105ra\u0161e) yra \u012fra\u0161yti \u00a0keturi kompensuojamieji antikoaguliantai: Apixabanum, Dabigatranum, Rivaroxabanum ir Edoxabanum. Nuo 2022 m. liepos 5 d. kei\u010diasi \u0161i\u0173 vaist\u0173 kompensavimo s\u0105lygos pacientams, sergantiems prie\u0161ird\u017ei\u0173 virp\u0117jimu, plau\u010di\u0173 embolija ir gili\u0173j\u0173 ven\u0173 tromboze. Kompensuojam\u0173j\u0173 antikoaguliant\u0173 skyrimo s\u0105lyg\u0173 pakeitimai buvo suderinti su gydytojais specialistais ir Lietuvos kardiolog\u0173 draugija. Draugijos vertinimu, patikslinus skyrimo s\u0105lygas, kompensuojamuosius antikoaguliantus gal\u0117s gauti bent pus\u0117 vis\u0173 didel\u0117s rizikos pacient\u0173.<\/p>\n<p>Nuo 2022 m. liepos 5 d. pacientams, sergantiems prie\u0161ird\u017ei\u0173 virp\u0117jimu ar plazd\u0117jimu, \u0161ie Privalomojo sveikatos draudimo fondo (PSDF) l\u0117\u0161omis kompensuojami vaistai gal\u0117s b\u016bti skiriami esant 2 (vyrams) ar 3 (moterims) ir daugiau insulto rizikos balams pagal klinikinio prognozavimo taisykles.<\/p>\n<p>Pacientams, sergantiems plau\u010di\u0173 embolija ir gili\u0173j\u0173 ven\u0173 tromboze, nuo 2022 m. liepos 5 d. \u0161ie vaistai gal\u0117s b\u016bti skiriami be papildom\u0173 prie\u0161 tai vartot\u0173 vaist\u0173 apribojim\u0173 (iki \u0161iol galiojo tvarka, kad antikoaguliantai nurodytoms diagnoz\u0117ms gydyti gal\u0117jo b\u016bti skiriami, kai gydymas varfarinu buvo kontraindikuotinas arba nepavykus parinkti tinkamos doz\u0117s). Ta\u010diau vaistai \u0161ioms indikacijoms gydyti gal\u0117s b\u016bti skiriami ne ilgesniam kaip 6 m\u0117n. laikotarpiui.<\/p>\n<p>\u0160iems pakeitimams, kuri\u0173 buvo laukiama nuo 2018 m. pabaigos, po \u012fvykusi\u0173 deryb\u0173 su vaist\u0173 gamintojais, \u00a0bus skirta apie 6,3 mln. eur\u0173 i\u0161 PSDF per metus.<\/p>\n<p>Antikoaguliant\u0173 vartojimas ma\u017eina rizik\u0105 patirti insult\u0105, tromboembolij\u0105 ir susirgti kitomis \u0161irdies bei kraujagysli\u0173 ligomis, kurios yra da\u017eniausia mirties prie\u017eastis Lietuvoje.<\/p>\n<p>Sveikatos apsaugos ministro \u012fsakym\u0105 ir atnaujintas vaist\u0173 skyrimo s\u0105lygas rasite\u00a0<a href=\"https:\/\/www.e-tar.lt\/portal\/lt\/legalAct\/fd6a5e60f24311ec8fa7d02a65c371ad\" target=\"_blank\" rel=\"noopener\">\u010cIA<\/a>.<\/p>\n<p><a href=\"https:\/\/sam.lrv.lt\/lt\/kontaktai-ziniasklaidai\"><em>SAM Informacija\u00a0<\/em><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dar daugiau didel\u0117s rizikos pacient\u0173, apdraust\u0173 privalomuoju sveikatos draudimu, gal\u0117s \u012fsigyti kompensuojam\u0173j\u0173 kraujo kre\u0161\u0117jim\u0105 stabdan\u010di\u0173 vaist\u0173 (antikoaguliant\u0173). Tai pasiekta Sveikatos apsaugos ministerijai patikslinus \u0161i\u0173 vaist\u0173 kompensavimo tvark\u0105. Numatoma, kad i\u0161laidos antikoaguliantams suma\u017e\u0117s beveik 9 t\u016bkst. \u017emoni\u0173, kurie dabar \u0161iuos vaistus \u012fsigyja savo l\u0117\u0161omis.\u00a0 Lig\u0173 ir kompensuojam\u0173j\u0173 vaist\u0173 joms gydyti s\u0105ra\u0161e (A s\u0105ra\u0161e) yra \u012fra\u0161yti \u00a0keturi&hellip;<\/p>\n","protected":false},"author":15,"featured_media":22800,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[6],"tags":[],"class_list":["post-22799","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-naujienos","category-6","description-off"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7kWFe-5VJ","jetpack_featured_media_url":"https:\/\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/07\/20402_24261e79e101a2baeef145fcc78b1724.png","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts\/22799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/comments?post=22799"}],"version-history":[{"count":1,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts\/22799\/revisions"}],"predecessor-version":[{"id":22801,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts\/22799\/revisions\/22801"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/media\/22800"}],"wp:attachment":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/media?parent=22799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/categories?post=22799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/tags?post=22799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}